Microbiota-centered interventions to boost immune checkpoint blockade therapies
Open accessThe DOI matches its Crossref record; 139 of the 140 references it cites were found in a registry or an index, and 1 are not checked yet; 68 of the 183 sources its claims cite were checked for support.
Abstract
Immune checkpoint blockade therapies have markedly advanced cancer treatment by invigorating antitumor immunity and extending patient survival. However, therapeutic resistance and immune-related toxicities remain major concerns. Emerging evidence indicates that microbial dysbiosis diminishes therapeutic response rates, while a diverse gut ecology and key beneficial taxa correlate with improved treatment outcomes. Therefore, there is a growing understanding that manipulating the gut microbiota could boost therapy efficacy. This review examines burgeoning methods that target the gut microbiome to optimize therapy and innovative diagnostic tools to detect dysbiosis, and highlights challenges that remain to be addressed in the field.
Verified 2026-11-19 · 1 reference not checked yet
Overview
CoChat Summary
TL;DR
This review argues that gut microbial dysbiosis limits immune checkpoint blockade (ICB) efficacy and increases immune-related adverse events, while microbiota-centered interventions (MCIs) such as FMT, probiotics, prebiotics, synbiotics, and diet may boost responses. It surveys diagnostic tools for dysbiosis and ongoing clinical trials, but concludes that standardized definitions, mechanistic clarity, and larger validation studies are still needed.
Key findings
- Antibiotic exposure near ICB initiation is linked to worse outcomes; a meta-analysis of ∼46,000 patients found the most pronounced detrimental effect when antibiotics were taken from 60 days before to 42 days after ICB start.
- Specific taxa correlate with response, including *Akkermansia muciniphila*, *Faecalibacterium prausnitzii*, and *Bifidobacterium* spp.; *A. muciniphila* shows a nonlinear effect, with both absence and abundance >77th percentile (>4.779%) associated with dismal overall survival in lung and urinary tract malignancies.
- FMT trials report promising signals: in the randomized TACITO trial, FMT plus axitinib/pembrolizumab in mRCC improved 1-year PFS (66.7% vs 35.0%, P = 0.036), ORR (54% vs 28%), and median PFS (14.2 vs 9.2 mo); a phase I melanoma trial of healthy-donor FMT with anti-PD-1 achieved ORR 65%.
- Probiotic CBM588 supplementation in mRCC was associated with improved ORR (74% vs 20%) and 6-month PFS (84% vs 60%), while the MET-4 consortium trial showed a response rate of ∼35% (6/17) vs 14% (1/7) in control, with clinical benefit in 53% vs 20%.
Methods
- Narrative review focused on PD-1 blockade and anti-CTLA-4 therapies, synthesizing preclinical and clinical evidence on the gut microbiome’s role in ICB efficacy and toxicity.
- Discusses diagnostic approaches including 16S rRNA sequencing, shotgun metagenomics, alpha/beta diversity, machine learning classifiers, GMHI, and TOPOSCORE, which uses 37 resistance-linked species (SIG1) and 45 response-linked species (SIG2).
- Summarizes MCIs—diet, FMT, probiotics, prebiotics, synbiotics—and tabulates ongoing clinical trials from ClinicalTrials.gov combining these interventions with immunotherapy.
Limitations
- The paper states there is no universally accepted definition of dysbiosis, and the precise nature of imbalance—taxonomic change versus disrupted host regulation—remains debated.
- It notes that FMT mechanisms are only partially understood, donor screening carries pathogen-transmission risk, and donor–recipient compatibility factors are poorly understood; probiotic safety concerns include bacteremia risk and possible negative effects on ICB efficacy.
- Evident from the text: this is a narrative review without systematic search or quantitative synthesis, and many cited MCI trials are ongoing, preliminary, or not yet recruiting, limiting definitive conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
50 Valid · 5 Not valid · 83 Not checked · 31 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Similarly, Bacteroides ovatus, Prevotella copri (renamed Segatella copri), Ruminococcus gnavus (renamed Mediterraneibacter gnavus), and Clostridiumsymbiosum are negatively correlated with ICB efficacy in certain contexts, despite associations with positive outcomes with chemotherapy or other monoclonal antibody therapies in other studies (Di Luccia et al., 2024; Peters et al., 2019; Routy et al.,”
What the sources say
- Disputedcites Di Luccia et al., 2024 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Partly supportedcites Peters et al., 2019 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked yetcites Routy et al., 2018b
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thomas Gajewski in Chicago, Jennifer Wargo at the MD Anderson Cancer Centre, and our laboratory at the Gustave Roussy Cancer Centre in Paris later published seminal studies in the same 2018 issue of Science, demonstrating direct links between gut microbiota composition and the success of ICB in different cancer populations, including melanoma, non–small-cell lung cancer (NSCLC), and urothelial and”
What the sources say
- Partly supportedcites Gopalakrishnan et al., 2018 sourceExperimental — accuracy not yet measured
Our copy supports the melanoma half of the attribution: the abstract and Results (p. 1-2) report significant differences in gut microbiome diversity and composition (higher alpha diversity and Ruminococcaceae/Faecalibacterium in responders, Bacteroidales in non-responders) among 112 metastatic melanoma patients on anti-PD-1, with FMT into germ-free mice transferring response to anti-PD-L1 (Results, p. 6). However, the cohort is exclusively metastatic melanoma treated with anti-PD-1; no passage (searched: renal cell carcinoma/lung/bladder/urothelial, other cohorts, concurrent studies) reports data in non-small-cell lung, urothelial or kidney cancer, so those tumour types in the citing sentence are not this paper's findings. The paper itself also hedges its human conclusion ('the gut microbiome may modulate responses to anti PD-1 immunotherapy in melanoma patients', Discussion, p. 7), slightly weaker than 'demonstrated direct links'. (LLM, conf=0.80)
- Partly supportedcites Matson et al., 2018 sourceExperimental — accuracy not yet measured
Our copy of Matson et al. supports the melanoma half of the claim: the Abstract reports baseline stool analysis from 42 metastatic melanoma patients before anti–PD-1 with 'a significant association... between commensal microbial composition and clinical response,' and Fig. 3 shows fecal reconstitution of GF mice altering anti–PD-L1 efficacy. However, the paper does not itself report non–small-cell lung cancer, urothelial or kidney cancer results — the Discussion only notes that 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)' without specifying those tumors, so attributing the multi-cancer scope to this source overreaches. Additionally, the source frames its conclusion as an association and hedges causality ('our results suggest that the commensal microbiome may have a mechanistic impact'; 'composition of the commensal microbiota in patients is associated with therapeutic efficacy'), which is weaker than the citing sentence's 'demonstrated direct links.' (LLM, conf=0.78)
- Not checked yetcites Routy et al., 2018b
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This complex community of microorganisms—including bacteria, archaea, eukaryotes, fungi, and viruses—lives in the gastrointestinal tract (Donaldson et al., 2016) and influences systemic and tumor immunity (Derosa et al., 2022; Kim et al., 2023).”
What the sources say
- Supportedcites Derosa et al., 2022 source
The Introduction (p.1) states in the paper's own voice that 'the composition of the gut microbiota' influences 'peripheral immune tonus' (systemic immunity) and the effectiveness/antitumor activity of immune checkpoint blockade, citing germ-free and antibiotic-treated mouse data plus patient cohorts across cancer types. The paper's own results section 'Links between fecal Akk, the intestinal ecosystem and the tumor microenvironment' reports shifts in the tumor microenvironment associated with gut microbial composition, covering the tumor-immunity half of the claim. This is a broad background statement and our copy treats the topic exactly that way. (LLM, conf=0.85)
- Supportedcites Kim et al., 2023 source
The cited paper is built around exactly this point: its title states that prior antibiotics disrupt anti-PD-1 responses 'by altering the gut microbiome and systemic immune response,' and the Discussion (p. Discussion) writes that 'the cancer microbiome exerts a profound influence on the efficacy of immune checkpoint blockade' and that 'altering the gut microbiome can reprogram the tumor microenvironment and improve the therapeutic efficacy of PD-1 inhibitors.' The Results section 'Effects of pATB administration on gut microbiota and circulating immune cells' links reduced gut microbial diversity (e.g., loss of Lactobacillus gasseri) to systemic immune changes, i.e., expansion of exhaustive CD8+ T cells among circulating immune cells. As a broad background citation, Kim et al. 2023 clearly supports the claim that the gut microbiota influences systemic and tumor immunity; the only qualifier is that their evidence comes from antibiotic-induced microbiome disruption in advanced gastric cancer patients on PD-1 blockade rather than a direct microbiota-transfer experiment. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Additionally, researchers have shown that anti-PD-1 efficacy can be restored in mice that received FMT from nonresponders by supplementing them with specific bacterial species associated with favorable responses, such as A. muciniphila (Derosa et al., 2018; Routy et al., 2018a).”
What the sources say
- Supportedcites Derosa et al., 2018 source
The Main text of our copy states the mouse experiment explicitly: after FMT from responder vs non-responder patients, 'mice transplanted with NR feces patients and supplementation with A. muciniphila restored the anti-cancer activity of anti-PD-1 treatment.' The same passage identifies A. muciniphila as the commensal most significantly associated with favorable outcome in the NSCLC/RCC cohort (present in 69% of responders vs 34% of non-responders), and passage [6] reiterates its role in PD-1 response, so both the restoration claim and the 'species associated with favorable responses' qualifier are covered. (LLM, conf=0.90)
- Not checked yetcites Routy et al., 2018a
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additionally, families like Lachnospiraceae, Turicibacteraceae, and Prevotellaceae are more abundant in breast cancer patients achieving pathologic complete responses to trastuzumab-containing regimens (Di Modica et al., 2021).”
What the sources say
- Supportedcites Di Modica et al., 2021 source
The section on trastuzumab benefit in patients with HER2-positive breast cancer reports that patients who achieved pathologic complete response had gut microbiota enriched in Lachnospiraceae, Turicibacteraceae, and Prevotellaceae. It identifies these patients as receiving neoadjuvant therapy containing trastuzumab. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
70 more claims · 36 with their cited sources checked
Create a free account to see all 169 claims and to verify the 112 references still open.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 74
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have linked deficient SCFA production to conditions such as graft-versus-host disease and poor responses to cancer immunotherapies, spurring interest in SCFA supplementation or diets to restore microbial balance.15,77,88,146,147”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [88]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Introduction
“B. longum and Bifidobacterium adolescentis administration reduced antibiotics-induced resistance to ICB (Funayama et al., 2025).”
§ References
“Funayama, E., Hosonuma M., Tajima K., Isobe J., Baba Y., Murayama M., Narikawa Y., Toyoda H., Tsurui T., Maruyama Y., et al. 2025. Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Introduction
“A phase I clinical trial (NCT05865730) is currently underway”
§ Introduction
“NCT05865730 Oncobax-AK: Akkermansia massiliensis ICB NSCLC/RCC 122 2 France 10-01-2022 Recruiting”
Citations
Cites
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationImmune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Cited by
Gut microbiota: a promising new target in immune tolerance
Almansour, N., Al‐Rashed, F., Choudhry, K., Alqaderi, H. E., Sindhu, S. T. A. K., Al‐Mulla, F., & Ahmad, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1607388 · Cited by 58
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
“15,77,88,146,147 However, mouse models have highlighted inconsistencies in treatment outcomes following supplementation with SCFAs.”
Self-citationOral microbiome alterations after cancer treatment: a scoping review and analysis
Boksa, F. A., Leinbach, L. I., Mody, D. P., Ganesan, S. M., & Mays, J. W. (2025) · Medical Oncology · doi:10.1007/s12032-025-02998-6 · Cited by 19
“Emerging evidence suggests the gut microbiome may modulate the efficacy of immune (ICI), with microbiome-targeted interventions showing potential to enhance ICI therapeutic response [20, 21].”
Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy
Grafanaki, K., Maniatis, A., Anastogianni, A., Bania, A., Pasmatzi, E., & Stathopoulos, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124193 · Cited by 13
Gambichler, T., Weyer-Fahlbusch, S. S., Overbeck, J., Rached, N. A., Becker, J. C., & Susok, L. (2025) · Cancers · doi:10.3390/cancers17111872 · Cited by 10
Metadata
- Authors
- Almonte, A. A., Thomas, S., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- Corresponding author
- Zitvogel, Laurence
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2025-04-22
- Volume
- 222
- Issue
- 7
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC12013646
- OpenAlex
- W4409654026
- Cited by
- 19
- References
- 140
- Citations by year
- 2026: 9 · 2025: 10
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- Institut Gustave-Roussy
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- immune checkpoint blockade, gut microbiota, microbiota-targeted interventions, cancer immunotherapy, dysbiosis, treatment resistance, immune-related adverse events, antitumor immunity, microbiome diagnostics
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Humans, Immunotherapy, Neoplasms, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbiota-centered interventions to boost immune checkpoint blockade therapies. https://app.cochat.ai/papers/10.1084/jem.20250378
- The paper
- Almonte, A. A., Thomas, S., & Zitvogel, L. (2025). Microbiota-centered interventions to boost immune checkpoint blockade therapies. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20250378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.